## Marin Veldic

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6057357/publications.pdf

Version: 2024-02-01

185998 133063 3,643 73 28 59 h-index citations g-index papers 79 79 79 3845 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14602-14607.	3.3	335
2	DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 348-353.	3.3	285
3	In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2152-2157.	3.3	249
4	GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology, 2005, $180$ , $191\text{-}205$ .	1.5	237
5	From The Cover: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1587-1592.	3.3	210
6	Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Molecular Psychiatry, 2007, 12, 385-397.	4.1	173
7	Down-regulation of neurosteroid biosynthesis in corticolimbic circuits mediates social isolation-induced behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18736-18741.	3.3	160
8	REELIN and Schizophrenia:: A Disease at the Interface of the Genome and the Epigenome. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2002, 2, 47-57.	3.4	146
9	Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophrenia Research, 2007, 91, 51-61.	1.1	137
10	DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1749-1754.	3.3	124
11	An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophrenia Research, 2009, 111, 115-122.	1.1	117
12	Neurosciences in the Third Millennium: A Tribute to Mimo Costa. Critical Reviews in Neurobiology, 2004, 16, $\nu$ .	3.3	106
13	S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. NeuroReport, 2007, 18, 57-60.	0.6	89
14	Reviewing the Role of DNA (Cytosine-5) Methyltransferase Overexpression in the Cortical GABAergic Dysfunction Associated with Psychosis Vulnerability. Epigenetics, 2007, 2, 29-36.	1.3	86
15	Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. Journal of Affective Disorders, 2016, 191, 216-221.	2.0	62
16	GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Review of Neurotherapeutics, 2009, 9, 87-98.	1.4	60
17	Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. Translational Psychiatry, 2015, 5, e689-e689.	2.4	60
18	Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. International Journal of Bipolar Disorders, 2015, 3, 30.	0.8	55

#	Article	IF	Citations
19	Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. Journal of Affective Disorders, 2022, 302, 385-400.	2.0	54
20	The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review. International Journal of Molecular Sciences, 2020, 21, 826.	1.8	47
21	GABAergic Cortical Neuron Chromatin as a Putative Target to Treat Schizophrenia Vulnerability. Critical Reviews in Neurobiology, 2003, 15, 121-142.	3.3	45
22	Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. Translational Psychiatry, 2018, 8, 188.	2.4	44
23	Pharmacogenomics of antidepressant induced mania: A review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. Journal of Affective Disorders, 2012, 136, e21-e29.	2.0	36
24	Association of Cytomegalovirus and <i>Toxoplasma gondii</i> Antibody Titers With Bipolar Disorder. JAMA Psychiatry, 2019, 76, 1285.	6.0	36
25	A Review of Epigenetics of PTSD in Comorbid Psychiatric Conditions. Genes, 2019, 10, 140.	1.0	36
26	Metabotropic glutamate receptors as emerging research targets in bipolar disorder. Psychiatry Research, 2017, 257, 327-337.	1.7	35
27	<scp>DNA</scp> Methylation/Demethylation Network Expression in Psychotic Patients with a History of Alcohol Abuse. Alcoholism: Clinical and Experimental Research, 2013, 37, 417-424.	1.4	31
28	Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of Affective Disorders, 2014, 169, S17-S23.	2.0	29
29	Clinical features of bipolar spectrum with binge eating behaviour. Journal of Affective Disorders, 2016, 201, 95-98.	2.0	29
30	Clinical Risk Factors and Serotonin Transporter Gene Variants Associated With Antidepressant-Induced Mania. Journal of Clinical Psychiatry, 2015, 76, 174-180.	1.1	27
31	Differential SLC1A2 Promoter Methylation in Bipolar Disorder With or Without Addiction. Frontiers in Cellular Neuroscience, 2017, 11, 217.	1.8	26
32	Alterations in levels of 8-Oxo-2'-deoxyguanosine and 8-Oxoguanine DNA glycosylase 1 during a current episode and after remission in unipolar and bipolar depression. Psychoneuroendocrinology, 2020, 114, 104600.	1.3	25
33	<scp>CLUMSY VEIN</scp> , the Arabidopsis <scp>DEAH</scp> â€box Prp16 ortholog, is required for auxinâ€mediated development. Plant Journal, 2015, 81, 183-197.	2.8	24
34	Genome-wide DNA methylomic differences between dorsolateral prefrontal and temporal pole cortices of bipolar disorder. Journal of Psychiatric Research, 2019, 117, 45-54.	1.5	24
35	Epigenetic Targets in GABAergic Neurons to Treat Schizophrenia. Advances in Pharmacology, 2006, 54, 95-117.	1.2	23
36	Genetic Risk Score Analysis in Early-Onset Bipolar Disorder. Journal of Clinical Psychiatry, 2017, 78, 1337-1343.	1.1	21

#	Article	IF	CITATIONS
37	Association of brainâ€derived neurotrophic factor ( <i><scp>BDNF</scp></i> ) Val66Met polymorphism with earlyâ€onset bipolar disorder. Bipolar Disorders, 2015, 17, 645-652.	1.1	20
38	EAAT2 as a Research Target in Bipolar Disorder and Unipolar Depression: A Systematic Review. Molecular Neuropsychiatry, 2019, 5, 44-59.	3.0	20
39	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	1.7	20
40	Genetic variant in SLC1A2 is associated with elevated anterior cingulate cortex glutamate and lifetime history of rapid cycling. Translational Psychiatry, 2019, 9, 149.	2.4	19
41	Longâ€ŧerm lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study. Bipolar Disorders, 2021, 23, 715-723.	1.1	19
42	A genome wide association study suggests the association of muskelin with early onset bipolar disorder: Implications for a GABAergic epileptogenic neurogenesis model. Journal of Affective Disorders, 2017, 208, 120-129.	2.0	17
43	Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A metaâ€analysis of randomized controlled trials. Bipolar Disorders, 2020, 22, 109-120.	1.1	17
44	L-methionine decreases dendritic spine density in mouse frontal cortex. NeuroReport, 2010, 21, 543-548.	0.6	16
45	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. Journal of Affective Disorders, 2019, 246, 62-68.	2.0	16
46	Effect of neuropsychiatric medications on mitochondrial function: For better or for worse. Neuroscience and Biobehavioral Reviews, 2021, 127, 555-571.	2.9	15
47	A neurochemical basis for an epigenetic vision of psychiatric disorders (1994–2009). Pharmacological Research, 2011, 64, 344-349.	3.1	14
48	Type 1 equilibrative nucleoside transporter (ENT1) regulates sexâ€specific ethanol drinking during disruption of circadian rhythms. Addiction Biology, 2020, 25, e12801.	1.4	13
49	Methylation of Brain Derived Neurotrophic Factor (BDNF) Val66Met CpG site is associated with early onset bipolar disorder. Journal of Affective Disorders, 2020, 267, 96-102.	2.0	13
50	Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Frontiers in Pharmacology, 2019, 10, 83.	1.6	12
51	Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review. Frontiers in Pharmacology, 2020, 11, 467.	1.6	12
52	Differential Dorsolateral Prefrontal Cortex Proteomic Profiles of Suicide Victims with Mood Disorders. Genes, 2020, 11, 256.	1.0	9
53	Neurochemical Basis for an Epigenetic Vision of Synaptic Organization. International Review of Neurobiology, 2004, 59, 73-91.	0.9	8
54	Symptoms of bipolar disorder are associated with lower bariatric surgery completion rates and higher food addiction. Eating Behaviors, 2021, 40, 101462.	1.1	8

#	Article	IF	CITATIONS
55	Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. International Journal of Bipolar Disorders, 2020, 8, 23.	0.8	8
56	Should allosteric positive modulators of GABAA receptors be tested in the treatment of schizophrenia? Schizophrenia Research, 2005, 73, 367-368.	1.1	7
57	Body mass index and blood pressure in bipolar patients: Target cardiometabolic markers for clinical practice. Journal of Affective Disorders, 2021, 282, 637-643.	2.0	7
58	Gene expression of methylation cycle and related genes in lymphocytes and brain of patients with schizophrenia and non-psychotic controls. Biomarkers in Neuropsychiatry, 2021, 5, 100038.	0.7	7
59	Chronic caffeine exposure in adolescence promotes diurnal, biphasic mood-cycling and enhanced motivation for reward in adult mice. Behavioural Brain Research, 2019, 370, 111943.	1.2	6
60	Label-free proteomics differences in the dorsolateral prefrontal cortex between bipolar disorder patients with and without psychosis. Journal of Affective Disorders, 2020, 270, 165-173.	2.0	6
61	Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders. Journal of Clinical Psychopharmacology, 2021, 41, 681-686.	0.7	6
62	The genetics of bipolar disorder with obesity and type 2 diabetes. Journal of Affective Disorders, 2022, 313, 222-231.	2.0	6
63	Increased plasma levels of 8â€oxoguanine DNA glycosylaseâ€1 in bipolar disorder. Psychiatry and Clinical Neurosciences, 2019, 73, 719-720.	1.0	5
64	Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies. Journal of Affective Disorders, 2022, 310, 150-155.	2.0	5
65	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. Journal of Psychiatric Research, 2017, 95, 208-212.	1.5	4
66	Plasma Cell-Free DNA Methylomics of Bipolar Disorder With and Without Rapid Cycling. Frontiers in Neuroscience, 2021, 15, 774037.	1.4	4
67	The role of base excision repair in major depressive disorder and bipolar disorder. Journal of Affective Disorders, 2022, 306, 288-300.	2.0	4
68	Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity. Journal of Affective Disorders, 2021, 295, 156-162.	2.0	3
69	Clinical and Genetic Correlates of Bipolar Disorder With Childhood-Onset Attention Deficit Disorder. Frontiers in Psychiatry, 2022, 13, 884217.	1.3	3
70	450. In Bipolar Disorder, SLC1A2 Promoter Hypomethylation is Associated with Binge Eating Disorder and Nicotine Dependance. Biological Psychiatry, 2017, 81, S183-S184.	0.7	1
71	Reelin Downregulation as a Prospective Treatment Target for GABAergic Dysfunction in Schizophrenia., 2008,, 341-363.		1
72	Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder. Journal of Clinical Psychopharmacology, 2022, 42, 159-162.	0.7	1

#	Article	IF	CITATIONS
73	Differences in perceived life stress in bipolar I and II disorder: Implications for future epigenetic quantification. Personalized Medicine in Psychiatry, 2022, 33-34, 100093.	0.1	O